Detailed programme Enrol now
Detailed Speaker Info
Prof Dr jan de maeseneer
Director International Centre for Primary Health Care and Family Medicine at Ghent University & Chair Expert Panel on effective ways of investing in Health (EXPH) at European Commission
Session: Plenary keynote - Competition amongst healthcare providers: Insights from the European Commission
Jan De Maeseneer, MD, PhD, is Head of the Department of Family Medicine and Primary Health Care and Vice-Dean for Strategic Planning in the Faculty of Medicine and Health Sciences at Ghent University (Belgium). He is also the Director of the International Centre for Primary Health Care and Family Medicine (Ghent University), a WHO Collaborating Center on PHC; the Chair of the European Forum for Primary Care (www.euprimarycare.org); and was the chair of the European Commission’s Expert Panel on ‘Effective Ways of Investing in Health’ from 2013 until 2016. His research topics and publications include healthcare systems reform, primary healthcare, health systems research, global health, physician payment systems, multi-morbidity and chronic care. Dr De Maeseneer is Associate Editor for the International Journal BMC Family Practice, and the Chair of the Flemish Strategic Advisory Board on Welfare, Health and Family in the Flemish Community from 2007 until 2015. Since 2005, he has served as the Secretary General of The Network: Towards Unity for Health (www.the-networktufh.org).
Journalist and host of current affairs programme Terzake at VRT
Session: Plenary debate - Competition: the answer in times of austerity?
Kathleen Cools is one of the VRT News service’s most prominent faces, on both radio and television. She has presented almost all of the major news and current affairs programmes at the public broadcaster. In 2013, she was honoured with a Flemish TV Star as best presenter. Her reputation as an experienced and talented interviewer and moderator is rock solid.
Director General at EFPIA − European Federation of Pharmaceutical Industries and Associations
Session: A European market perspective from the research-based pharmaceutical industry
Richard Bergstrom is a pharmacist by training. He received his MScPharm degree from the University of Uppsala, Sweden, in 1988. Until 1992, he worked at the Medical Products Agency as Assistant Head of Registration. He then moved to Switzerland, where he worked for 9 years in regulatory affairs at Roche and Novartis. He has also served as Director of EU Regulatory Strategy at Roche Basel and as Director-General of LIF, the Swedish Pharmaceutical Industry Association. Since 2006, he has been an advisor to the World Health Organisation on Good Governance in Medicine; and, since April 2011, he has been the Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Dr Raf Mertens
General Director at KCE − Belgian Health Care Knowledge Centre
Session: Different perspectives on containing costs of medicines
Dr Raf Mertens obtained his diploma in medicine at K.U.Leuven in 1981. He then worked as a physician for 4 years in Kivu (Congo). From 1985 to 1997, he was in charge of the national programme for monitoring hospital-acquired infections at the ISSP (Institut Scientifique de Santé Publique). At the same time, he continued his studies as a medical hygienist (1986, at K.U.Leuven) and epidemiologist (1989, at the London School of Tropical Medicine and Hygiene), working for 4 years as the coordinator of the European HELICS programme for the harmonisation of registration networks for hospital-acquired infections. In 1997, at the Alliance Nationale des Mutualités Chrétiennes, Dr Mertens became responsible for healthcare data analysis and feedback and the development of quality promotion programmes, mainly in collaboration with hospitals. Since 2006, he has been the head of the Research and Development department of the Mutualités Chrétiennes. In addition, since 2001 he has been actively involved in the development of the Agence Intermutualiste (AIM-IMA). He is the vice-president of the Conseil National pour la Promotion de la Qualité des soins de santé (CNPQ) and a member of the Board of Directors of the Belgian Health Care Knowledge Centre (KCE). As from 2009, he was appointed General Manager of the KCE.
Head of Market Access and Medical Affairs at Roche Diagnostics
Session: From cost to competitive value in diagnostics: the beMedTech view
As the Head of Market Access and Medical Affairs for Roche Diagnostics Belgium, Alex Lefevre represents the voice of beMedTech at the Vlerick Healthcare Conference. beMedTech (former UNAMEC) is the federation of the medical technologies industry and includes more than 200 companies, accounting for 80% of the market.
Jan De Kerpel
PhD, MBA − Executive Director at Kempen & Co
Session: Demystification of the banking position: what are global financing trends in the bio/life science market?
Jan De Kerpel is a seasoned biotech/healthcare business and finance expert with more than 20 years of experience in the fields of drug development, equity analysis and growth financing. Prior to Kempen & Co, he was Senior Equity Analyst, Pharma & Biotech at KBC Securities, an R&D director at Devgen (now Syngenta) and senior scientist at Tibotec-Virco (now JNJ). He has a proven track record in successfully identifying investment opportunities to a continuously expanding international investor base and has been instrumental in raising close to €1 billion in equity financing for numerous Benelux biotech, medtech, health services and pharmaceutical companies. He is also a board member of FlandersBio.
MBA, CEO at eTheRNA Immunotherapies NV
Session: Lessons learned from a serial entrepreneur: critical success factors within the different growth stages
A university-trained pharmacist, Dirk Reyn holds an MBA degree and is a seasoned entrepreneur in the international pharmaceutical industry with a 30-year track record. He was the founder and CEO of MOVETIS, a public (Euronext) biopharmaceutical spin-off company from Janssen Pharmaceutica, which was acquired by Shire in 2010. He also founded Progress Pharma, an asset development company. Currently, he is the CEO of eTheRNA, a joint project between VUB Brussels and Progress Pharma. He is also active as a Business Angel investor in both pharma and non-pharma companies, and he is a member of a number of pharma think tanks. Dirk serves as a board member of FlandersBio, Tigenix, and Zembra.
Partner at Advance.Healthcare & Co-Founder Healthstartup.eu
Session: Experience from the health start-up scene: how to build better businesses
Developing software in healthcare as autodidact since 1990. Managing a nursing home since 1995. Building expertise in digital health since 2005. Organising intense healthcare innovation initiatives since 2011 (Healthstartup & Advance.Healthcare).
CFO at Biocartis
Session: Moving from start-up to established grower: the Biocartis case through a strategic finance lens
Ewoud Welten is Chief Financial Officer of Biocartis, a company active in highly innovative molecular diagnostics solutions. In September 2014, Biocartis launched its molecular diagnostics platform Idylla™ as a revolutionary mini-lab that provides fast, accurate and highly reliable molecular information for high-precision diagnosis of cancer and infectious diseases. Today, Biocartis has 5 cancer tests and 2 infectious disease tests on the market. Ewoud Welten has been CFO since 2015. Previously, he worked for financial institutions, including ABN AMRO and the investment bank Kempen & Co., where he was Vice President Corporate Finance with a focus on the life sciences sector, and where he led various international capital market transactions including IPOs, secondary fundraisings, and mergers and acquisitions. In that capacity, he was also involved in Biocartis’ stock-market flotation. Ewoud holds a Master’s degree in Financial Economics from Erasmus University Rotterdam.
Prof Dr Kris Vanhaecht
Assistant Professor Quality in Healthcare at KU Leuven
Session: The quality of care and its impact on the competition between healthcare providers
Kris Vanhaecht is Assistant Professor in Quality Management in Healthcare at KULeuven and has been working in the field of care process improvement and quality control since 1998. Kris is coordinator of the research line on quality & patient safety of the new KULeuven Institute for Healthcare Policy (Leuvens Instituut voor Gezondheidszorgbeleid – LIGB). Currently, he is the Secretary General of the European Pathway Association and is international coordinator of international studies on care pathways for COPD, Hip Fracture, Acute Coronary Syndrome and Gastro-Intestinal Cancer patients. He is part-time academic policy advisor to the management team and the quality department of Leuven University Hospitals and also collaborates with Dutch hospitals on quality and leadership development.
Prof Dr Filip Dewallens
Professor of Hospital Governance and Law at KU Leuven & Universiteit Antwerpen, and Managing Partner at Dewallens & Partners law firm
Session: How does a growing level of clustering between doctors lead to more intermediate competition on a regional level?
Filip Dewallens is Professor in Healthcare Law at KU Leuven and the University of Antwerp, and he has been a visiting professor at the University of Ljubljana (Slovenia). Since 1996, Filip has also been the president of the Flemish Association of Health Law. Between 2004 and 2009, Filip was a member of the board of ZiekenhuisNetwerk Antwerpen, Belgium’s largest hospital group. Since 2013, Filip has been a member of KU Leuven’s board of governors. On the international level, Filip has undertaken consulting work for the IMF, the World Bank (Macedonia 1997 and 2007, Slovenia 2004), and the Council of Europe (Montenegro 2008, Serbia 2009).
Prof Dr Carol Propper
CBE, FBA, Professor of Economics at Imperial College London
Session: Hospitals and competition: a view from the NHS and its reforms
Carol is a Professor of Economics at Imperial College Business School in the Organisation & Management Group. Carol joined Imperial College Business School as Professor of Economics and Head of the new Health Management Group on 1 October 2007. She also holds an appointment at the University of Bristol, where she helped found the Centre for Market and Public Organisation, which has attracted major research funding from a number of bodies. Carol was Senior Economic Advisor to NHS Executive on Regulation of the NHS Internal Market 1993-4, Co-Director of the Centre for the Analysis of Social Exclusion at London School of Economics from 1997-2007, Co-Director and Director of the Centre for Market and Public Organisation from 1998-2009, and chaired the ESRC research grants board until 2009. Carol has been awarded a CBE for her services to social science − the accolade recognises Carol’s research into public economics and economics of healthcare as well as her work with colleagues from other social science and medical disciplines.
General Director at Santeon Hospital Group
Session: The impact of a value-based strategy on competition between hospital networks: lessons from the Netherlands
Leonique Niessen is Director of the Programme Office at Santeon Hospital Group. Santeon was founded in 2010 and emerged from the Association of Collaborative Hospitals to encourage open collaboration amongst the 6 Santeon hospitals, with the aim of improving medical care through continuous innovation.
Prof Dr Walter Van Dyck
Director Vlerick Healthcare Management Centre
Session: Monitor of the track "Competing for access"
Prof Dr Miguel Meuleman
Associate Professor of Entrepreneurship at Vlerick Business School
Session: Monitor of the track "Competing for capital"
Prof Dr Brecht Cardoen
Head of the MINOZ research centre at Vlerick Business School
Session: Monitor of the track "Competing for patients"
Prof. Dr. MARISA MIRALDO
Associate Professor in Health Economics at Imperial College London
Session: The impact of regulation and competition on pharmaceutical innovation
Marisa joined the Imperial College Business School and the Health Care Management Group as an Assistant Professor in Economics in 2008. In the past she has held academic appointments at the Centre for Health Economics and the Department of Economics and Related Studies both at the University of York. Marisa holds a PhD in economics from York University, a MSc in Economics and Finance from Universitat Pompeu Fabra, a Master of Arts in Economics from Université Catholique de Louvain and a first degree in economics from Universidade Católica Portuguesa. Marisa has developed expertise in public policy and pharmaceutical economics by having participated in research projects commissioned by the Department of Health focusing on topics such as competition and regulation in secondary and primary care, competition between public and private providers and the impact of public policy on Pharmaceutical firms' strategies. She is particularly interested in regulation and competition in the health care sector and, more generally, in the public sector.
dr. CRHIS VAN HUL
Medical Expert at Onafhankelijke Ziekenfondsen
Session: Improving access to medicines by tilting the balance towards societal priority setting
Dr Chris Van Hul obtained his degree in medicine at K.U.Leuven in 1978. He then specialised in neuro-psychiatry. From 1983 till 1992 he worked as a neurologist at the Municipal Hospital in Diest where he was a member (and for many years also vice-chairman) of the Medical Board. In 1997 he obtained an additional degree (DES) in ‘évaluation du dommage corporel’ from the University of Brussels. Since 1993 he is active at the Independent Health Insurance Funds (Onafhankelijke Ziekenfondsen) where he is a staff member in the “Study & Strategy" division. Dr Van Hul also represents the Independent Health Insurance Funds, among others, in the College of Medical Directors and the Insurance Committee. He was also involved in the discussions surrounding drugs as a member of the "Working Group on Article 81" (negotiation of temporary contracts) of the CATT ("unmet medical need” procedure) and through the Special Solidarity Fund. He is married and the proud father of five children.
Prof. Dr. johan kips
CEO CUB Erasme Brussels
Session: Plenary debate - Competition: the answer in times of austerity?
Professor Dr Johan Kips is a lung specialist by training and was long associated with Ghent University. After leading UZ Leuven for 6 years (until 2013) and serving as general chief medical officer at AZ Sint-Jan Brugge, he transferred to Zorgnet Vlaanderen in 2015. Here he succeeded Dr Daniël Devos as sector head of the general hospitals. Johan Kips is one of the spiritual fathers of ‘Together We Count. Towards a patient-focused funding of general hospitals’ − a text that sets out the framework for a new hospital financing. At the beginning of this year, he made another career move to Erasmus Hospital in Brussels. Dr Kips has numerous scientific publications to his name. Between 2001 and 2005, he was advisor to the cabinets of Frank Vandenbroucke and Rudy Demotte.
Detailed programme Enrol now